PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12021256-6	2002	Consistently, the amount of GTP-Rac increased significantly by Y-27632 in LPA-stimulated cells.	Y 27632	63-70	AKT serine/threonine kinase 1	Homo sapiens	32-35	
12105187-10	2002	Treatment with Y-27632 or ML-7 that inhibits myosin phosphorylation and contractility increased lamellipodia through Rac activation and decreased cell polarization.	Y 27632	15-22	AKT serine/threonine kinase 1	Homo sapiens	117-120	
11956113-13	2002	Akt dephosphorylation by thrombin was blocked by both simvastatin and Y-27632.	Y 27632	70-77	AKT serine/threonine kinase 1	Homo sapiens	0-3	
9668072-8	1998	Consistently, Rho/Rac chimeras containing either region can induce stress fibers in transfected HeLa cells, and this induction is suppressed by treatment with Y-27632, a specific inhibitor of ROCK kinases.	Y 27632	159-166	AKT serine/threonine kinase 1	Homo sapiens	18-21	
28415790-9	2017	The small GTPase, Rho, was also activated by HG stimulation, and pretreatment of HBMECs with Y27632, a Rho-associated kinase (ROCK) inhibitor, rescued HG-impaired Akt-eNOS signaling.	Y 27632	93-99	AKT serine/threonine kinase 1	Homo sapiens	163-166	
31718896-0	2019	Y-27632 preserves epidermal integrity in a human skin organ-culture (hSOC) system by regulating AKT and ERK signaling pathways.	Y 27632	0-7	AKT serine/threonine kinase 1	Homo sapiens	96-99	
31718896-6	2019	RESULTS: We found Y-27632 not only enhanced both basal cell proliferation and expression of suprabasal cell differentiation markers, but also maintained the balance of keratinocyte proliferation and differentiation through activation of AKT pathways on one hand and inhibition of ERK pathways on the other hand.	Y 27632	18-25	AKT serine/threonine kinase 1	Homo sapiens	237-240	
28701359-8	2017	Blocking Rho with C3 or its downstream target ROCK with Y27632 significantly inhibited oxLDL-induced Akt phosphorylation and proliferation mediated by both Cu2+- and LPO-oxLDL.	Y 27632	56-62	AKT serine/threonine kinase 1	Homo sapiens	101-104	
32297701-8	2020	Y-27632 also reversed the activation of PTEN, the inactivation/dephosphorylation of PI3K/Akt and down-regulation of VEGF.	Y 27632	0-7	AKT serine/threonine kinase 1	Homo sapiens	89-92	
31871589-8	2019	Experimentally, the induced state was generated by increasing the cellular betaPIX (a Rac-GEF) level and/or decreasing ROCK (a Rac-GAP effector protein) activity with Y-27632 (a ROCK-inhibitor).	Y 27632	167-174	AKT serine/threonine kinase 1	Homo sapiens	127-130	
20959118-8	2011	Furthermore, Akt inhibitor restored the loss of vinculin-stained focal adhesion formation induced by Y27632.	Y 27632	101-107	AKT serine/threonine kinase 1	Homo sapiens	13-16	
20126978-7	2010	Interestingly, EGF-induced phosphorylation of both Akt and glycogen synthase kinase-3beta (GSK-3beta), but not p44/p42 mitogen-activated protein (MAP) kinase, were dose-dependently enhanced when the cells were pretreated with Y27632 or fasudil, another Rho-kinase inhibitor.	Y 27632	226-232	AKT serine/threonine kinase 1	Homo sapiens	51-54	
18165899-5	2008	Y-27632 treatment reduced I/R-induced apoptosis by 31% (P < 0.01) and maintained Akt activity.	Y 27632	0-7	AKT serine/threonine kinase 1	Homo sapiens	84-87	
18854312-10	2008	The pathway by which RhoA mediates cardiomyocyte Akt activation is demonstrated to require Rho kinase, FAK and PI3K, but not Src, based on studies with pharmacological inhibitors (Y-27632, LY294002, PF271 and PP2) and inhibitory protein expression (FAK-related nonkinase).	Y 27632	180-187	AKT serine/threonine kinase 1	Homo sapiens	49-52